Jeffrey Holt, MD
Ophthalmology · Hot Springs, ARNPI 1326364456
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.9% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Alcon accounts for 68.5% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2021 at $956 and has fallen 50.2% since, to $476 in 2025. Among ophthalmology clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 105 payments — averaging $41.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Rxsight Inc$388
- Bausch & Lomb Americas Inc.$270
- Bausch & Lomb, A Division Of Bausch Health US, LLC$202
- AbbVie$144
- Carl Zeiss Meditec USA, Inc.$115
- plus $266 from 8 others
What the payments were for
- Travel & lodging$3578%
- Food & beverage$4,03992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 53 | $3,012 |
| Rxsight Inc | 10 | $388 |
| Bausch & Lomb Americas Inc. | 13 | $270 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $202 |
| AbbVie | 7 | $144 |
| Carl Zeiss Meditec USA, Inc. | 1 | $115 |
| Tarsus Pharmaceuticals, Inc. | 2 | $55 |
| Eyevance Pharmaceuticals LLC | 2 | $42 |
| Sight Sciences, Inc. | 2 | $37 |
| Aerie Pharmaceuticals, Inc. | 2 | $35 |
| Oyster Point Pharma, Inc. | 1 | $27 |
| Rayner Intraocular Lenses Limited | 2 | $26 |
| Thea Pharma Inc. | 1 | $23 |
| Novartis | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARGOS$380
- DAILIES$357
- Clareon$344
- AcrySof IQ VIVITY IOL$275
- RXSIGHT CONTACT LENS$231
- RXSIGHT INJECTOR CARTRIDGE$231
- RXSIGHT INJECTOR HANDPIECE$231
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$231
- Precision 1$125
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$120
- CIRRUS HD-OCT$115
- LIGHT ADJUSTABLE LENS (LAL)$112
- Wavelight$108
- AcrySof IQ PanOptix$102
How this compares
$4,396 in reported general payments places this provider in the 90th percentile of 125 ophthalmology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 73 | $31,990 |
| RestasisCyclosporine | 17 | $10,968 |
| XiidraLifitegrast | 12 | $8,445 |
| Latanoprost | 521 | $6,239 |
| CombiganBrimonidine Tartrate/Timolol | 24 | $5,852 |
| Prednisolone Acetate | 163 | $4,798 |
| Travoprost | 22 | $3,822 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 126 | $2,197 |
| Brimonidine Tartrate | 97 | $1,958 |
| Timolol Maleate | 157 | $1,763 |
| Ciprofloxacin Hcl | 83 | $951 |
| Dorzolamide Hcl | 35 | $522 |
| ErythromycinErythromycin Base | 28 | $284 |
| Acyclovir | 14 | $215 |
| Tobramycin | 29 | $108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $144 | $48,810114 claims |
| Bausch & Lomb Americas Inc.Xiidra | $270 | $8,44512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 125 ophthalmology providers in Arkansas.
Other ophthalmology in Hot Springs
- Daniel SinesRogers$81K
- Mike McFarlandPine Bluff$63K
- Jennifer DoyleLittle Rock$38K
- James LinderMarion$18K
- Matthew MargolisJonesboro$17K
- Thomas StankJonesboro$16K
- Andrew PerinNorth Little Rock$4K
- Joshua LittleJonesboro$4K
- Jonathan CascianoLittle Rock$4K
- Christian HesterLittle Rock$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.